Saghmos Therapeutics Granted Japanese Patent for Phase 3-Ready ST-62516

Saghmos Therapeutics, Inc., a biopharmaceutical company based in Greenwich, Connecticut, announced that the Japanese Patent Office has granted Japanese Patent No. 7474463 for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator. This patent, which provides exclusivity until 2037, includes broad claims for reducing acute kidney injury (AKI) in patients with chronic kidney disease (CKD) undergoing procedures involving contrast dyes.

Anna Kazanchyan, MD, the Founder and CEO of Saghmos Therapeutics, expressed enthusiasm about the expansion of the company's patent portfolio. She noted that this new Japanese patent complements an already issued US patent and a Notice of Allowance for a second US patent.

Saghmos Therapeutics is focused on the development of ST-62516 to mitigate the risk of AKI and Major Adverse Cardiac and Kidney Events (MACKE) following contrast procedures like percutaneous coronary intervention (PCI). The company has recently entered a collaboration with the Duke Clinical Research Institute (DCRI) to enhance and plan the operational aspects of its Phase 3 study.

In the United States, over one million PCI procedures are performed each year on individuals with ischemic heart disease, including those who have suffered a myocardial infarction (heart attack). Approximately half of these patients have additional health issues such as chronic kidney disease, diabetes, or are aged 75 and older. These comorbidities, along with certain procedure-related factors, can compromise the safety of PCI and elevate the risk of AKI and MACKE. At present, there are no FDA-approved medications specifically designed to address this significant medical need. ST-62516 holds potential to benefit not just patients with comorbidities but all individuals undergoing PCI by diminishing the risk of AKI and MACKE.

Saghmos Therapeutics is dedicated to reducing the risk of cardiorenal complications following PCI through the development of ST-62516 (trimetazidine). The company has secured a US patent (Patent number 11,123,345) for the prevention and treatment of AKI after contrast procedures and has received a Notice of Allowance for an additional US patent. Recently, the company announced the appointments of Fred Hassan as Chairman of the Board of Directors and Dr. Stephen Grant as Chief Regulatory Officer.